Table 6.
The frequencies of antifungal usage in patients from 2013 to 2017
| Antifungal agent | Patients n (%)c | |||||
|---|---|---|---|---|---|---|
| Total (n = 243) | 2013 (n = 20) | 2014 (n = 29) | 2015 (n = 44) | 2016 (n = 74) | 2017 (n = 76) | |
| Amphotericin B(i.v.) | 49 (20.2) | 6(30.0%) | 5 (17.2) | 13 (29.5) | 17 (23.0) | 8 (10.5) |
| Fluconazolea(i.v.) | 122 (52.8) | 11 (55.0%) | 20 (69.0) | 19 (43.2) | 30 (40.5) | 42 (55.3) |
| Voriconazole(i.v.) | 84 (34.6) | 8 (40.0) | 10 (34.5) | 15 (34.1) | 27 (36.5) | 24 (31.6) |
| otherb | 20(13.3) | 0 | 0 | 0 | 15(20.3) | 5(6.5) |
i.v. intravenous
aC. krusei is excluded
bother including caspofungin (intravenous) and itraconazole (oral)
cSome patients used more than two kind of antifungal drugs during the course of treatment